|RFx ID :||21651899|
|Tender Name :||Provision of Avastin Syringes|
|Reference # :||Avastin_SDHB_RFQ_2019|
|Open Date :||Tuesday, 24 September 2019 12:00 AM (Pacific/Auckland UTC+12:00)|
|Close Date :||Friday, 18 October 2019 10:00 AM (Pacific/Auckland UTC+13:00)|
|Tender Type :||Request for Quotations (RFQ)|
|Tender Coverage :||Sole Agency [?]|
|Exemption Reason :||None|
|Required Pre-qualifications :||None|
|Alternate Physical Delivery Address :||as per details in RFQ documents|
|Alternate Physical Fax Number :|
|Agency Address :|
Currently, the SDHB Pharmacy Aseptic Production Unit at Dunedin hospital prepares Avastin® syringes and supplies these to the ophthalmology department across Southern DHB. Avastin® has been shown to radically improve visual outcomes in patients with age related macular degeneration (AMD) and is used extensively within Southern DHB for patients with AMD. Once Avastin is initiated for AMD, it is considered a lifelong treatment.
Avastin also has been proven to improve and/or preserve vision in patient with diabetes, retinal vein occlusions and in some ocular inflammatory conditions. Given the growth of Avastin® use, we are seeking to obtain a long term sustainable supply to meet the predicted on-going growth.
Please note that responses will be considered alongside the option of maintaining or increasing in-house capacity to meet some or all of the demand. Therefore one possible outcome of the RFQ process is that SDHB will decide to continue with in-house production of Avastin® and not appoint an external provider, or appoint an external provider only to complement SDHB’s production.
No Winner SDHB made the decision to consider compounding of Avastin syringes in-house rather than move to an outsourced model.